Status report Coegin Pharma – A new approach to cancer therapy
18 December, 2020
Nordic biotech Coegin Pharma is responding to calls for new, innovative cancer therapeutics by offering a novel approach through inhibition of a well-validated target, the cPLA₂α enzyme. Since October 2020, the company has been listed on NGM Nordic SME, and, with an experienced board and management team, Coegin Pharma is executing on its new strategic focus on cancer treatments. BioStock has now published a status report of the company, which can be downloaded below.
In 2021, Coegin Pharma is planning to initiate a phase I/II trial in actinic keratosis (AK), a common precancerous skin condition. The company is developing an effective, less invasive therapy than current treatments and with a better safety profile. The medical need is great for new therapies in AK, which also implies a substantial commercial potential. A first readout from the study is expected already in the beginning of 2022.
Coegin Pharma will expand into other indications, such as basal cell carcinoma, triple negative breast cancer and leukaemia. The company aims to select its systemic drug candidate in Q1 2021.
Inhibition of the cPLA₂α enzyme has also shown promising preclinical results in chronic kidney disease, a project that can potentially be spun out in the future.
Dowload the status report below.
Disclaimer
This analysis is a Status Report by BioStock, conducted on commission by the analysed company. BioStock’s remuneration for the work has been agreed upon beforehand and is independent of the content and conclusions reached in the analysis. The content of this analysis is based solely on publicly available information gathered through research by the analyst from sources such as e.g. financial reports and statements, the company’s web page, public presentations and in dialogue with representatives of the company’s executive management. The information about the company was made available to the company for fact-checking and was published subsequent approval by the company. The analysis contains subjective assessments regarding future events and outcomes which should be considered to render such assessments to be uncertain. Any valuation of the company, products and/or markets has been made by BioStock’s analyst. The analyst does not own shares in the company. This analysis should not be considered as a recommendation or advice to invest in the company nor shall it be interpreted as financial advice of any sort. BioStock can not and does not give any guarantees that the conclusions or forecasts presented in this analysis will be fulfilled. BioStock can not be held responsible or liable for any damage, direct or indirect, caused by decisions made based on the information in this analysis. BioStock is not subject to the oversight of the Swedish financial authority Finansinspektionen and is thus not required to comply with the specific rules and guidelines that apply to analysis firms subject to the oversight of Finansinspektionen.
Prenumerera på BioStocks nyhetsbrev
